{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Thymoglobulin+%28ATG%29&page=2", "query": { "intervention": "High Dose Thymoglobulin (ATG)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 50, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Thymoglobulin+%28ATG%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Thymoglobulin+%28ATG%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T17:00:03.750Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00709592", "title": "Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Leukemia", "Multiple Myeloma", "Acute Myeloid Leukemia", "Hodgkin Lymphoma", "Chronic Lymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Thymoglobulin", "type": "BIOLOGICAL" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Allogeneic PBSCT or BMT", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION", "PROCEDURE", "DRUG" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "40 Years to 70 Years" }, "enrollment_count": 42, "start_date": "2008-07-21", "completion_date": "2017-06-28", "has_results": true, "last_update_posted_date": "2018-11-09", "last_synced_at": "2026-10-07T17:00:03.750Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00709592" }, { "nct_id": "NCT00716066", "title": "Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autoimmune Disease", "Neurologic Autoimmune Disease", "Autologous Transplant Autoimmune", "Multiple Sclerosis Transplant", "MS Stem Cell Transplant", "Multiple Sclerosis Stem Cell Transplant", "Stiff Person Syndrome", "HCT for Neurologic Autoimmune Disorders", "CIDP Transplant", "Myasthenia Gravis Transplant", "Autoimmune Nervous System Disorder", "Central Nervous System Vasculitis", "Cerebellar Degeneration", "Chronic Inflammatory Demyelinating Polyneuropathy", "Lambert Eaton Myasthenic Syndrome", "Myasthenia Gravis", "Neuromyelitis Optica", "Opsoclonus Myoclonus Syndrome", "Rasmussen Subacute Encephalitis" ], "interventions": [ { "name": "Anti-Thymocyte Globulin", "type": "BIOLOGICAL" }, { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Syngeneic Bone Marrow Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "71 Years", "sex": "ALL", "summary": "Up to 71 Years" }, "enrollment_count": 53, "start_date": "2008-06", "completion_date": "2030-01-31", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-07T17:00:03.750Z", "location_count": 3, "location_summary": "Denver, Colorado • Seattle, Washington", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00716066" }, { "nct_id": "NCT02029638", "title": "BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "acetaminophen", "type": "DRUG" }, { "name": "diphenhydramine", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "bone marrow transplant", "type": "BIOLOGICAL" }, { "name": "MESNA", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "filgrastim", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 4, "start_date": "2014-01-07", "completion_date": "2017-09-06", "has_results": true, "last_update_posted_date": "2018-09-24", "last_synced_at": "2026-10-07T17:00:03.750Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02029638" }, { "nct_id": "NCT02441803", "title": "Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI)", "type": "RADIATION" }, { "name": "Thymoglobulin", "type": "DRUG" }, { "name": "Stem Cell Infusion", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 11, "start_date": "2015-09-14", "completion_date": "2021-09-22", "has_results": true, "last_update_posted_date": "2024-02-22", "last_synced_at": "2026-10-07T17:00:03.750Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02441803" }, { "nct_id": "NCT03292861", "title": "The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Heart Transplantation" ], "interventions": [ { "name": "Thymoglobulin", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Corticosteroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 60, "start_date": "2018-09-13", "completion_date": "2026-03-31", "has_results": false, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-10-07T17:00:03.750Z", "location_count": 2, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03292861" }, { "nct_id": "NCT00782821", "title": "Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "Rabbit Antithymocyte Globulin", "type": "DRUG" }, { "name": "Velcade", "type": "DRUG" }, { "name": "Rituxan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 40, "start_date": "2008-09", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2016-01-20", "last_synced_at": "2026-10-07T17:00:03.750Z", "location_count": 2, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00782821" }, { "nct_id": "NCT01758328", "title": "Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "busulfan", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "fludarabine", "type": "DRUG" }, { "name": "anti-thymocyte globulin (ATG)", "type": "BIOLOGICAL" }, { "name": "a T cell depleted stem cell transplant", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "21 Years to 72 Years" }, "enrollment_count": 29, "start_date": "2012-12", "completion_date": "2025-03-17", "has_results": false, "last_update_posted_date": "2025-03-20", "last_synced_at": "2026-10-07T17:00:03.750Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01758328" }, { "nct_id": "NCT00278564", "title": "Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "MYOPATHY" ], "interventions": [ { "name": "Hematopoietic stem cell transplantation", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "ATG(rabbit)", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Rituxan", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "16 Years to 65 Years" }, "enrollment_count": 7, "start_date": "2005-09", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2018-08-06", "last_synced_at": "2026-10-07T17:00:03.750Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00278564" }, { "nct_id": "NCT06872333", "title": "Allo HSCT for High Risk Hemoglobinopathies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Failure", "Sickle Cell Disease", "Hemoglobinopathies" ], "interventions": [ { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Cell Infusion", "type": "BIOLOGICAL" }, { "name": "Thymoglobulin", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Plerixafor (mozobil)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": "55 Years", "sex": "ALL", "summary": "Up to 55 Years" }, "enrollment_count": 62, "start_date": "2024-11-19", "completion_date": "2032-06-01", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-07T17:00:03.750Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06872333" }, { "nct_id": "NCT00409695", "title": "Thymoglobulin (ATG) Dose Finding Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Graft vs Host Disease" ], "interventions": [ { "name": "Low Dose Thymoglobulin (ATG)", "type": "DRUG" }, { "name": "High Dose Thymoglobulin (ATG)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1, "start_date": "2006-12", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2012-01-23", "last_synced_at": "2026-10-07T17:00:03.750Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00409695" } ] }